Intraperitoneal VEGF inhibition using bevacizumab: A potential approach for the symptomatic treatment of malignant ascites?

Oncologist

Volumn 14, Issue 12, 2009, Pages 1242-1251

  Kobold, Sebastian ^a   Hegewisch Becker, Susanna ^b   Oechsle, Karin ^a   Jordan, Karin ^c   Bokemeyer, Carsten ^a   Atanackovic, Djordje ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Martin Luther University Halle Wittenberg ^*

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Bevacizumab; Catumaxomab; Malignant ascites; VEGF

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; BLEOMYCIN; CATUMAXOMAB; CISPLATIN; DIURETIC AGENT; DOXORUBICIN; FLUOROURACIL; THIOTEPA; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; ASCITES; BLEEDING; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; HUMAN; HYPERTENSION; INFECTION; LIVER TOXICITY; LUNG EDEMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALIGNANT ASCITES; NAUSEA; NONHUMAN; PARACENTESIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; QUALITY OF LIFE; REVIEW; SODIUM RESTRICTION; UNSPECIFIED SIDE EFFECT; WOUND HEALING;

ANTIBODIES, MONOCLONAL; ASCITES; HUMANS; INJECTIONS, INTRAPERITONEAL; PERITONEAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 75449099345     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0109     Document Type: Review

References (122)

1. Runyon BA. Care of patients with ascites. N Engl J Med 1994;330:337-342.
2. Sherer DM, Eliakim R, Abulafia O. The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. Gynecol Obstet Invest 2000;50:217-224.
3. Dobson HD. Malignant ascites. In: Saclarides TJ, Milikan KW, Godellas CV, eds. Surgical Oncology. New York: Springer Verlag, 2006:704-709.
4. Rosenberg SM. Palliation of malignant ascites. Gastroenterol Clin North Am 2006;35:189-199, xi.
5. Markman M. Intraperitoneal antineoplastic drug delivery: Rationale and results. Lancet Oncol 2003;4:277-283.
6. Facchiano E, Scaringi S, Kianmanesh R et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol 2008;34:154-158.
7. Becker G, Galandi D, Blum HE. Malignant ascites: Systematic review and guideline for treatment. Eur J Cancer 2006;42:589-597.
8. Malik I, Abubakar S, Rizwana I et al. Clinical features and management of malignant ascites. J Pak Med Assoc 1991;41:38-40.
9. Sharma S, Walsh D. Management of symptomatic malignant ascites with diuretics: Two case reports and a review of the literature. J Pain Symptom Manage 1995;10:237-242.
10. Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. J Pain Symptom Manage 1998;16:96-101.
11. Barnett TD, Rubins J. Placement of a permanent tunneled peritoneal drainage catheter for palliation of malignant ascites: A simplified percutaneous approach. J Vasc Interv Radiol 2002;13:379-383.
12. Adam RA, Adam YG. Malignant ascites: Past, present, and future. J Am Coll Surg 2004;198:999-1011.
13. Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg 1996;83: 6-14.
14. Aslam N, Marino CR. Malignant ascites: New concepts in pathophysiology, diagnosis, and management. Arch Intern Med 2001;161:2733-2737.
15. Ströhlein MA, Siegel R, Jäger M et al. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 2009;28:18.
16. Burges A, Wimberger P, Kümper C et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I/II study. Clin Cancer Res 2007; 13:3899 -3905.
17. Ruf P, Gires O, Jäger M et al. Characterisation of the new EpCAMspecific antibody HO-3: Implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007;97:315-321.
18. Heiss MM, Ströhlein MA, JägerMet al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005;117:435-443.
19. Parsons S, Murawa PX, Koralewski P et al. Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/ III study. J Clin Oncol 2008;26(15 suppl):3000.
20. Schmelzer E, Reid LM. EpCAM expression in normal, non-pathological tissues. Front Biosci 2008;13:3096-3100.
21. Sebastian M, Passlick B, Friccius-Quecke H et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): A phase I study. Cancer Immunol Immunother 2007;56:1637-1644.
22. Walton L, Nottingham JM. Palliation of malignant ascites. J Surg Educ 2007;64:4 -9.
23. Chernow B, Sahn SA. Carcinomatous involvement of the pleura: An analysis of 96 patients. Am J Med 1977;63:695-702.
24. Meyer PC. Metastatic carcinoma of the pleura. Thorax 1966;21:437- 443.
25. Feldman GB, Knapp RC. Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. Am J Obstet Gynecol 1974;119:991-994.
26. Feldman GB, Knapp RC, Order SE et al. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 1972;32:1663-1666.
27. Brown H. Kinetics of angiogenesis in small vessels related to mouse parietal peritoneum. Anat Rec 1976;184:364.
28. Heuser LS, Taylor SH, Folkman J. Prevention of carcinomatosis and bloody malignant ascites in the rat by an inhibitor of angiogenesis. J Surg Res 1984;36:244-250.
29. Senger DR, Galli SJ, DvorakAMet al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985.
30. Senger DR, Perruzzi CA, Feder J et al. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629-5632.
31. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851- 858.
32. Keck PJ, Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-1312.
33. Olson TA, Mohanraj D, Carson LF et al. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 1994;54:276-280.
34. Santin AD, Hermonat PL, Ravaggi A et al. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 1999;20:177-181.
35. Stadlmann S, Amberger A, Pollheimer J et al. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol Oncol 2005;97:784-789.
36. Yeo KT, Wang HH, Nagy JA et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 1993;53:2912-2918.
37. Freeman MR, Schneck FX, Gagnon ML et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis. Cancer Res 1995;55:4140-4145.
38. Shibuya M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 1995;67:281-316.
39. Dvorak HF, Sioussat TM, Brown LF et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med 1991;174:1275-1278.
40. Folkman J, Watson K, Ingber D et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
41. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1004.
42. Weidner N, Semple JP, Welch WR et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324: 1-8.
43. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
44. Leung DW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
45. Conn G, Bayne ML, Soderman DD et al. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci U S A 1990;87:2628-2632.
46. Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
47. Barton DP, Cai A, Wendt K et al. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 1997;3:1579-1586.
48. Kassim SK, El-Salahy EM, Fayed ST et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004;37:363-369.
49. Kido S, Kitadai Y, Hattori N et al. Interleukin 8 and vascular endothelial growth factor - prognostic factors in human gastric carcinomas? Eur J Cancer 2001;37:1482-1487.
50. Volm M, Koomägi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997;74:64-68.
51. Matsuyama W, Hashiguchi T, MizoguchiAet al. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 2000;118:948-951.
52. Ugurel S, Rappl G, Tilgen W et al. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001;19:577-583.
53. Kumar H, Heer K, Lee PW et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998;4:1279-1285.
54. Li L, Wang L, ZhangWet al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res 2004;24:1973-1979.
55. Cooper BC, Ritchie JM, Broghammer CL et al. Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer. Clin Cancer Res 2002;8:3193-3197.
56. Nagy JA, Herzberg KT, Masse EM et al. Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice. Cancer Res 1989;49:5448-5458.
57. Nagy JA, Herzberg KT, Dvorak JM et al. Pathogenesis of malignant ascites formation: Initiating events that lead to fluid accumulation. Cancer Res 1993;53:2631-2643.
58. Luo JC, Yamaguchi S, Shinkai A et al. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res 1998;58:2652-2660.
59. Luo JC, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 1998;58:2594-2600.
60. Shibuya M, Luo JC, ToyodaMet al. Involvement of VEGF and its receptors in ascites tumor formation. Cancer Chemother Pharmacol 1999; 43(suppl):S72-S77.
61. Liu CD, Tilch L, Kwan D et al. Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer. J Surg Res 2002;102: 31-34.
62. Yoneda J, Kuniyasu H, Crispens MA et al. Expression of angiogenesisrelated genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998;90:447-454.
63. Akutagawa N, Nishikawa A, Iwasaki M et al. Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: Association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model. Jpn J Cancer Res 2002;93:644-651.
64. Hu L, Hofmann J, Zaloudek C et al. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002;161: 1917-1924.
65. Nagy JA, Masse EM, Herzberg KT et al. Pathogenesis of ascites tumor growth: Vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995;55:360-368.
66. Kanayama H, Yano S, Kim SJ et al. Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice. Clin Exp Metastasis 1999;17:831-840.
67. Byrne AT, Ross L, Holash J et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721-5728.
68. Manenti L, Riccardi E, Marchini S et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther 2005;4:715-725.
69. Zhang L, Yang N, Garcia JR et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 2002;161:2295-2309.
70. Yano S, Shinohara H, Herbst RS et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000;157:1893-1903.
71. Yanagawa H, Takeuchi E, Suzuki Y et al. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 1999;48:396-400.
72. Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999; 54:707-710.
73. Cheng D, Rodriguez RM, Perkett EA et al. Vascular endothelial growth factor in pleural fluid. Chest 1999;116:760-765.
74. Kraft A, Weindel K, Ochs A et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178-187.
75. Zebrowski BK, Yano S, Liu W et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999;5:3364-3368.
76. Zebrowski BK, Liu W, Ramirez K et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999;6:373-378.
77. Verheul HM, Hoekman K, Jorna AS et al. Targeting vascular endothelial growth factor blockade: Ascites and pleural effusion formation. The Oncologist 2000;5(suppl 1):45-50.
78. Lim SC, Jung SI, Kim YC et al. Vascular endothelial growth factor in malignant and tuberculous pleural effusions. J Korean Med Sci 2000;15: 279-283.
79. Ishimoto O, Saijo Y, Narumi K et al. High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncology 2002; 63:70-75.
80. Kishiro I, Kato S, Fuse D et al. Clinical significance of vascular endothelial growth factor in patients with primary lung cancer. Respirology 2002; 7:93-98.
81. Momi H, Matsuyama W, InoueKet al. Vascular endothelial growth factor and proinflammatory cytokines in pleural effusions. Respir Med 2002;96: 817-822.
82. Dong WG, Sun XM, Yu BP et al. Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J Gastroenterol 2003;9: 2596-2600.
83. Yabushita H, Shimazu M, Noguchi M et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep 2003;10:89-95.
84. Hamed EA, El-Noweihi AM, Mohamed AZ et al. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. Respirology 2004;9:81-86.
85. Sack U, Hoffmann M, Zhao XJ et al. Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 2005;25:600-604.
86. Kalomenidis I, Kollintza A, Sigala I et al. Angiopoietin-2 levels are elevated in exudative pleural effusions. Chest 2006;129:1259-1266.
87. Shu J, Sun G, Liu H et al. Clinical utility of vascular endothelial growth factor in diagnosing malignant pleural effusions. Acta Oncol 2007;46: 1004-1011.
88. Bamias A, Koutsoukou V, Terpos E et al. Correlation of NK T-like CD3+CD56+cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol 2008;108:421-427.
89. Tomimoto H, Yano S, Muguruma H et al. Levels of soluble vascular endothelial growth factor receptor 1 are elevated in the exudative pleural effusions. J Med Invest 2007;54:146-153.
90. Atanackovic D, Cao Y, Kim JW et al. The local cytokine and chemokine milieu within malignant effusions. Tumour Biol 2008;29:93-104.
91. Harlozinska A, Sedlaczek P, Kulpa J et al. Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Res 2004;24:1149-1157.
92. Rudlowski C, Pickart AK, Fuhljahn C et al. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: A long-term follow-up. Int J Gynecol Cancer 2006;16(suppl 1):183-189.
93. Sönmezer M, Güngör M, Ensari A et al. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: In association with transforming growth factor beta and vascular endothelial growth factor. Int J Gynecol Cancer 2004;14:82-88.
94. Ke L, Qu H, Nagy JA et al. Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. Eur J Cancer 1996; 32A:2467-2473.
95. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249-1256.
96. Shaheen RM, Ahmad SA, Liu W et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85:584-589.
97. Xu L, Yoneda J, Herrera C et al. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 2000;16:445-454.
98. Matsumori Y, Yano S, Goto H et al. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res 2006;16:15-26.
99. Hu L, Hofmann J, Holash J et al. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005;11: 6966-6971.
100. Hotz HG, Hines OJ, Masood R et al. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery 2005;137:192-199.
101. Wang T, Cheng HH, Liu SM et al. Increased peritoneal membrane permeability is associated with abnormal peritoneal surface layer. Perit Dial Int 2001;21(suppl 3):S345-S348.
102. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
103. Varey AH, Rennel ES, Qiu Y et al. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: Balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 2008;98: 1366-1379.
104. Shaheen RM, Tseng WW, Vellagas R et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int J Oncol 2001;18:221-226.
105. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508.
106. Hurwitz H, Fehrenbacher L, NovotnyW et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
107. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
108. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
109. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
110. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
111. Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-8040.
112. de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: Metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005;69(suppl 3):46-56.
113. Pichelmayer O, Gruenberger B, Zielinski C et al. Bevacizumab is active in malignant effusion. Ann Oncol 2006;17:1853.
114. Pichelmayer O, Zielinski C, Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med 2005;353:740-741.
115. Numnum TM, Rocconi RP, Whitworth J et al. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006;102:425-428.
116. Hamilton CA, Maxwell GL, Chernofsky MR et al. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 2008;111:530-532.
117. El-Shami K, Elsaid A, El-Kerm Y. Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol 2007;25(18 suppl):9043.
118. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69(suppl 3):25-33.
119. Badgwell BD, Camp ER, Feig B et al. Management of bevacizumabassociated bowel perforation: A case series and review of the literature. Ann Oncol 2008;19:577-582.
120. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007;105:3-6.
121. Kesterson JP, Mhawech-Fauceglia P, Lele S. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: A case report. Gynecol Oncol 2008;111:527-529.
122. Hamilton CA, Maxwell GL, Chernofsky MR et al. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 2008;111:530-532.